324 related articles for article (PubMed ID: 22455857)
1. [Progress of targeted therapy related to K-ras mutation].
Li ZW; Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
[No Abstract] [Full Text] [Related]
2. [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
Enlund F; Helenius G; Palmqvist R; Edsjö A; Sundström M
Lakartidningen; 2010 Feb 3-9; 107(5):255-9. PubMed ID: 20297566
[No Abstract] [Full Text] [Related]
3. EGFR-targeted therapy.
Vecchione L; Jacobs B; Normanno N; Ciardiello F; Tejpar S
Exp Cell Res; 2011 Nov; 317(19):2765-71. PubMed ID: 21925171
[TBL] [Abstract][Full Text] [Related]
4. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
Nozawa K; Watanabe T
Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
[TBL] [Abstract][Full Text] [Related]
5. Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases.
Bösmüller H; Kranewitter W; Webersinke G; Rumpold H; Hackl M; Fend F
Pathol Res Pract; 2011 Jun; 207(6):399-402. PubMed ID: 21536390
[TBL] [Abstract][Full Text] [Related]
6. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
Hawkes E; Cunningham D
Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
[No Abstract] [Full Text] [Related]
7. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
Hawkes E; Cunningham D
J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
[No Abstract] [Full Text] [Related]
8. Therapeutic modulation of k-ras signaling in colorectal cancer.
Krens LL; Baas JM; Gelderblom H; Guchelaar HJ
Drug Discov Today; 2010 Jul; 15(13-14):502-16. PubMed ID: 20594936
[TBL] [Abstract][Full Text] [Related]
9. [Molecular pathology of lung cancer: key to personalized medicine].
Cheng L; Li Y; Zhang SB; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321
[No Abstract] [Full Text] [Related]
10. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.
Jiang Y; Mackley H; Cheng H; Ajani JA
Biomark Med; 2010 Aug; 4(4):535-41. PubMed ID: 20701442
[TBL] [Abstract][Full Text] [Related]
11. KRAS and BRAF: drug targets and predictive biomarkers.
Vakiani E; Solit DB
J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
[TBL] [Abstract][Full Text] [Related]
12. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
Tímár J; Láng I
Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
[TBL] [Abstract][Full Text] [Related]
13. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
[No Abstract] [Full Text] [Related]
15. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
[No Abstract] [Full Text] [Related]
16. Predictive factors to targeted treatment in gastrointestinal carcinomas.
Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
[TBL] [Abstract][Full Text] [Related]
17. [Targeting the RAS signalling pathway in cancer].
Mansi L; Viel E; Curtit E; Medioni J; Le Tourneau C
Bull Cancer; 2011 Oct; 98(9):1019-28. PubMed ID: 21715253
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy in first line treatment of RAS wild type colorectal cancer.
Formica V; Roselli M
World J Gastroenterol; 2015 Mar; 21(10):2871-4. PubMed ID: 25780283
[TBL] [Abstract][Full Text] [Related]
19. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
20. Should oncologists be aware in their clinical practice of KRAS molecular analysis?
Santini D; Galluzzo S; Gaeta L; Zoccoli A; Riva E; Ruzzo A; Vincenzi B; Graziano F; Loupakis F; Falcone A; Muda AO; Tonini G
J Clin Oncol; 2011 Mar; 29(8):e206-7; author reply e208-9. PubMed ID: 21263083
[No Abstract] [Full Text] [Related]
[Next] [New Search]
